Spark Therapeutics and Genethon announce collaboration

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Genethon, for the development and commercialization of an adeno-associated viral (AAV) gene therapy targeting the liver to address a rare genetic disease.

Spark Therapeutics has the option to develop and commercialize any gene therapy that results from the licensing agreement. Under the terms of the agreement, Genethon will collaborate with Spark Therapeutics on further preclinical research activities.